Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
Proceeds from the funding will be used to support the development of an oral vaccine candidate against Nipah virus (NiV) using the Company’s proprietary OraPro™ thermal stabilization technology.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Department of Health and Social Care
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Funding February 23, 2022
Details:
A trial of ChAdOx1 nCoV-19 in children and teens has been put on hold while the UK’s drug regulator investigates a possible link between the jab and rare blood clots in adults.
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: Covishield
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: University of Oxford
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2021
Details:
Gout medication colchicine will be tested in a large UK study looking into potential early-stage COVID-19 treatments and enrollment criteria was widened for the latest arm of the trial.
Lead Product(s): Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
The initial study will help scientists understand how the immune system reacts to coronavirus (the virus that causes Covid-19), and identify factors that influence how the virus is transmitted.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2021
Details:
The direct delivery of Foralumab to the nasal passage and respiratory tract rapidly suppresses lung inflammation, as evident from the CT scans. The treatment also improved the senses of smell and taste in treated patients.
Lead Product(s): Foralumab,Dexamethasone
Therapeutic Area: Infections and Infectious Diseases Product Name: TZLS-401
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
Details:
AstraZeneca will begin testing whether they can improve the efficacy of AZD1222 by combining it with the Ad26 human adenoviral vector from Russia’s Sputnik V vaccine.
Lead Product(s): ChAdOx1 nCoV-19,Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: The Gamaleya National Center of Epidemiology and Microbiology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
Details:
In the trial the patients will inhale two puffs twice a day for 14 days providing a 400 microgram dose of budesonide/dose. The PRINCIPLE trial is evaluating whether treatment prescribed in the first 14 days of Covid-19 illness can speed up recovery and prevent hospitalization.
Lead Product(s): Budesonide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2020
Details:
In the study, the patients, who were in multiple hospitals across Italy and Spain, had a 71 per cent reduced risk of dying compared to patients who had not taken the drug (baricitinib).
Lead Product(s): Baricitinib
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
Nafamostat works by affecting the body's own enzymes—not the virus, which is capable of mutating to evade treatments. Nafamostat blocks TMPRSS2, the enzyme that enables SARS-CoV-2's spike proteins to gain entry into cells.
Lead Product(s): Nafamostat
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Covistat
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 06, 2020
Details:
Excivion has partnered with CPI to draw upon the company’s extensive experience in the optimisation and scale-up of biologics manufacturing processes to optimise the manufacture of their novel Zika vaccine antigen candidate, Zika-HX.
Lead Product(s): Zika-HX antigen
Therapeutic Area: Infections and Infectious Diseases Product Name: Zika vaccine
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: CPI
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 13, 2020
